Skip to main content

Table 2 One-way sensitivity analysis of discounted per-patient costs

From: Using decision-analysis modelling to estimate the economic impact of the identification of unrecognised bipolar disorder in primary care: the untapped potential of screening

Sensitivity analysis of discounted costs for patient presenting with new episode of MDD ($*)

Original input parameters

Sensitivity analysis

No screening

Delta Study

Savings

Prevalence of UBP in new MDD cases (16%)

    
 

Low estimate (11%)

49,140

48,622

518

 

High estimate (21%)

52,731

50,404

2327

Sensitivity & Specificity (0.76 , 0.87)

    
 

Low sensitivity, high specificity (0.58, 0.97)

50,936

49,255

1681

 

High sensitivity, low specificity (0.92, 0.75)

50,936

50,114

822

Cost of RBP relative to UBP (− 7604)

    
 

High estimate (150%, − 11,406)

57,424

55,869

1554

 

Low estimate (50%, − 3802)

44,448

43,157

1291

Cost of MDD relative to UBP (− 1936)

    
 

High estimate (150%, − 17,904)

74,718

69,732

4985

 

Low estimated (50%, − 5968)

27,154

29,293

− 2139

Cost of RBP relative to MDD (+4332)

    
 

RBP = MDD

64,919

63,055

1864

Annual probability of diagnosis correction (15%)

    
 

Low estimate (10%)

51,402

49,758

1644

 

High estimate (20%)

50,525

49,297

1228

Probability of psychiatric evaluation (75%)

    
 

Low estimate (50%)

50,936

50,728

207

 

High estimate (100%)

50,936

48,297

2638

  1. RBP: Recognised bipolar disorder patients; MDD: Major depressive disorder; UBP: Unrecognised bipolar disorder patients; CI: Confidence interval
  2. *Discounted costs expressed as 2021 USD